Merck & Co.
AWARDS
NEWS
The Dementia Discovery Fund (DDF), a venture capital fund focused solely on dementia-related investments, completed $350 million of fundraising. The initial target was $200 million.
The U.S. Food and Drug Administration (FDA) accepted Merck’s new supplemental Biologics License Application (sBLA) for Keytruda.
Nodthera, a U.K.-based startup, snagged $40 million (£28 million) in Series A funding.
Roche announced that its Phase III IMpower 133 clinical trial of Tecentriq (atezolizumab) plus carboplatin and etoposide chemotherapy met its co-primary endpoints.
It’s a big week for the U.S. Food and Drug Administration (FDA) with plenty of upcoming decisions including Achaogen, GW Pharma, Merck and more.
Novo Nordisk’s semaglutide, an oral GLP-1 analogue, continues to rack up positive Phase III clinical trial data compared to its competitors.
JOBS
IN THE PRESS